Pentagon Awards Glaxo $342m Contract For COVID Vaccines

The Pentagon on Thursday announced a $342 million contract has been awarded to British pharmaceutical giant GlaxoSmithKline to deliver “mass quantities of COVID-19 vaccines” … Continue reading Pentagon Awards Glaxo $342m Contract For COVID Vaccines

By Emmanuel Egobiambu

Updated July 31, 2020

Scientists are at work in the VirPath university laboratory, classified as “P3” level of safety, on February 5, 2020 as they try to find an effective treatment against the new SARS-like coronavirus, which has already caused more than 560 deaths. When most are busy developing vaccines or testing the few anti-virals available, VirPath will go after drugs used for diseases that have nothing to do with a respiratory infection such as 2019-nCoV. JEFF PACHOUD / AFP

Covid-19- vaccine — In this file photo taken on July 10, 2020 A photo shows vaccines in prefilled, single-use syringes before the inspection and packaging phase at the French pharmaceutical company Sanofi’s world distribution centre in Val de Reuil, France. JOEL SAGET / AFP

The Pentagon on Thursday announced a $342 million contract has been awarded to British pharmaceutical giant GlaxoSmithKline to deliver “mass quantities of COVID-19 vaccines” to US troops.

It said GSK was the only company to make a bid for the contract, which will consist of supporting “military locations and personnel throughout the continental US and outside the continental US.”

The work will be carried out in North Carolina “with an estimated completion date of Feb. 28, 2021,” the Pentagon said.

The US Army will supervise execution of the project.

AFP